Otsuka Pharmaceutical Co., Ltd. (OTSKF) on Friday announced the launch of Nexletol in Japan for the treatment of hypercholesterolemia and familial hypercholesterolemia.
In 2020, Otsuka had acquired development and commercialization rights for Nexletol in Japan through an agreement with Esperion Therapeutics, Inc.
Approved in Japan in September, Nexletol is already marketed for hypercholesterolemia in several regions around the world, including the United States and Europe.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.